KaydedilenlerDerginizi ekleyin

Dergiler / Balkan Medical Journal / 2016 / Cilt: 33 - Sayı: 5

Autosomal Dominant Polycystic Disease is Associated with Depressed Levels of Soluble Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand

Atıl BİSGİN
Funda SARI
Saadet GÜMÜŞLÜ
Ramazan ÇETİNKAYA
Gizem Esra GENÇ
Metin SARIKAYA
Arzu Didem YALÇIN
Sayfa
512–516
Yayın Tarihi
2022-10-11
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Conclusion: Our results show that ADPKD patients have depressed sTRAIL levels, indicating apoptosis unrelated to the stage of chronic renal failure

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Background: Autosomal dominant polycystic kidney disease (ADPKD) is characterized by multiple, large renal cysts and impaired kidney function.
📊
Temel Bulgular & Veri:Methods: Serum sTRAIL levels were measured in 44 patients with ADPKD and 18 healthy volunteers.
💡
Sonuç & Katkı:Conclusion: Our results show that ADPKD patients have depressed sTRAIL levels, indicating apoptosis unrelated to the stage of chronic renal failure
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Background: Autosomal dominant polycystic kidney disease (ADPKD) is characterized by multiple, large renal cysts and impaired kidney function. Although the reason for the development of kidney cysts is un-known, ADPKD is associated with cell cycle arrest and abundant apoptosis of renal tubular epithelial cells. Aims: We asked whether serum-soluble TNF-related apop-tosis-inducing ligand (sTRAIL) might underlie ADPKD.Study Design: Case-control study. Methods: Serum sTRAIL levels were measured in 44 patients with ADPKD and 18 healthy volunteers. The human soluble TRAIL/Apo2L ELISA kit was used for the in vitro quantitative determination of sTRAIL in serum samples.Results: Mean serum sTRAIL levels were lower in patients with ADPKD as compared to the con-trol group (446.9±103.1 and 875.9±349.6 pg/mL, p0.05). Conclusion: Our results show that ADPKD patients have depressed sTRAIL levels, indicating apoptosis unrelated to the stage of chronic renal failure

🔖

Bu Makaleye Atıf Yap

BİSGİN, A., SARI, F., GÜMÜŞLÜ, S., ÇETİNKAYA, R., GENÇ, G. E., SARIKAYA, M., YALÇIN, A. D. (2022). Autosomal Dominant Polycystic Disease is Associated with Depressed Levels of Soluble Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand. Balkan Medical Journal, Cilt: 33 - Sayı: 5, 512–516. https://ajindex.com/articles/461311

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (3)

  1. Gabow PA. Autosomal dominant polycystic kidney disease. N Engl J Med 1993;329:332-42. [CrossRef] Gattone VH 2nd, Calvet JP, Cowley BD Jr, Evan AP, Shaver TS, Helmstader K, et al. Autosomal recessive polycystic kidney disease in a murine model. A gross and microscopic description. Lab Invest 1988;59:231-8.
  2. Zhou XJ, Kukes G. Pathogenesis of autosomal dominant polyc- ystic kidney disease: role of apoptosis. Diagn Mol Pathol 1998;7:65-8. [CrossRef] Lanoix J, D'Agati V, Szabolcs M, Trudel M. Dysregulation of cellular proliferation and apoptosis mediates human autoso- mal dominant polycystic kidney disease (ADPKD). Oncogene 1996;13:1153-60. Woo D. Apoptosis and loss of renal tissue in polycystic kidney diseases. N Engl J Med 1995;333:18-25. [CrossRef] Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995;3:673- 82. [CrossRef] Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ash- kenazi A. Induction of apoptosis by Apo-2 ligand, a new mem- ber of the tumor necrosis factor cytokine family. J Biol Chem 1996;271:12687-90. [CrossRef] Corallini F, Rimondi E, Secchiero P. TRAIL and osteopro- tegerin: a role in endothelial physiopathology? Front Biosci 2008;13:135-47. [CrossRef] Pan G, O'Rourke K, Chinnaiyan AM, Gentz R, Ebner R, Ni J, et al. The receptor for the cytotoxic ligand TRAIL. Science 1997;276:111-3. [CrossRef] Walczak H, Degli-Esposti MA, Johnson RS, Smolak PJ, Waugh JY, Boiani N, et al. TRAIL-R2: a novel apoptosis-mediating re- ceptor for TRAIL. EMBO J 1997;16:5386-97. [CrossRef] Pan G, Ni J, Wei YF, Yu G, Gentz R, Dixit VM. An antago- nist decoy receptor and a death domain-containing receptor for TRAIL. Science 1997;277:815-8. [CrossRef] Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, et al. Control of TRAIL induced apoptosis by a family of signaling and decoy receptors. Science 1997;277:818-21. [CrossRef] Degli-Esposti MA, Dougall WC, Smolak PJ, Waugh JY, Smith CA, Goodwin RG. The novel receptor TRAIL-R4 induces NF- kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity 1997;7:813-20. [CrossRef] Shipman CM, Croucher PI. Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing li- gand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells. Cancer Res 2003;63:912-6.
  3. Smyth MJ, Takeda K, Hayakawa